| 肿瘤靶向抗体偶联物的研究进展 |
| |
| 引用本文： | 梁文,谢丽萍,胡又佳.肿瘤靶向抗体偶联物的研究进展[J].世界临床药物,2012(3):171-175. |
| |
| 作者姓名： | 梁文 谢丽萍 胡又佳 |
| |
| 作者单位： | 上海医药工业研究院 |
| |
| 摘 要： | 肿瘤靶向制剂已成为当今肿瘤治疗研究的热点,针对特定的靶点(抗原)可以制备相应的单抗。特异性单抗和蛋白毒素、放射性同位素、化疗药物偶联制备成相应的靶向抗体药物,这种抗体偶联物能增强药物的有效性,减少对正常组织的毒害。本文就三类肿瘤靶向抗体偶联物的特点、作用机制、上市药物以及发展趋势进行综述。
|
| 关 键 词： | 抗体偶联物 肿瘤 靶向治疗 |
Research progress on tumor-targeting immunoconjugate |
| |
| LIANG Wen,XIE Li-ping,HU You-jia.Research progress on tumor-targeting immunoconjugate[J].WORLD CLINICAL DRUGS,2012(3):171-175. |
| |
| Authors: | LIANG Wen XIE Li-ping HU You-jia |
| |
| Institution: | (Shanghai Institute of Pharmaceutical Industry,Shanghai 200437,China) |
| |
| Abstract: | Targeting cancer therapeutic agents have become the hot spot for cancer research recently.The appropriate targeting antibody drugs can be prepared for specific targets(antigens).Monoclonal antibodies conjugated to protein toxins,radioisotopes,and chemotherapy drugs can both improve efficacy and reduce systemic toxicity.This review summarizes the characteristics,mechanism,and the development trend of marketed drugs for the three types of tumor-targeting immunoconjugate. |
| |
| Keywords: | immunoconjugate cancer targeted therapy |
| 本文献已被 CNKI 等数据库收录！ |
|
